# **QEEG Clinical Report**

**EEGLens** 





The QEEG report is provided by NPCindex Company, operating under the QEEGhome brand.

### **Personal Data:**

Name: Asadollah Yadollahi

Gender: Male

Age: 1968-08-25 - 57.2

Handedness: Left

### **Clinical Data:**

Initial diagnosis: Parkinson

Medication: -

Date of Recording: 2025-10-12

Source of Referral: Dr Shabanzadeh

This case belongs to Dr Shabanzadeh











#### **EEG** Quality




#### Z-score Information






#### **■** TMS Reponsibility



#### ■ Pathological Assessment



#### **■ EEG Neuromarker Values**

Neuromarker	Region	Value	Assessment
APF - EO	Frontal	11.00	High
AFP - EC	Frontal	11.33	High
APF - EO	Occipital	10.88	High
AFP - EC	Occipital	11.62	High
Arousal Level - EO	-	-	High
Arousal Level - EC	-	-	High

QEEGhome Clinical Report


Dr Shabanzadeh






### **Denoising Information**

#### Eye Close



Rejected Channel





Flat Channel



# **Total Recording Time Remaining:**

39.01 sec

## **Number of Eye and Muscle Elements**

Eye: 1 Muscle: 0

Low Artifact Percentage


High Artifact Percentage

**Total Artifact Percentage** 

**EEG Quality:** good

#### Eye Open

#### Raw EEG







# **Total Recording Time Remaining:**

99.75 sec

### **Number of Eye and Muscle Elements**

Eye: 0 Muscle: 0

Low Artifact Percentage



High Artifact Percentage




Total Artifact Percentage



**EEG Quality:** perfect

#### Denoised EEG




Flat Channel





#### **Pathological Assessment**

#### Main Diagnosis: Depression



#### **Description**

According to the guidelines, the initial diagnosis of depression could have comorbidities such as alcohol abuse, panic attacks, OCD, and anxiety. It also differentially diagnoses with anxiety, bipolar disorder, alcohol abuse, psychosis, and somatoform.

In the above graph, the red area shows the percentage of each comorbidity from your patient's EEG markers. Observe that each comorbidity marker is not unique and can be shared with other comorbidities.

Side circles in the above graph represent the differential diagnosis between depression and its misdiagnosis conditions based on your patient's EEG markers and trained artificial intelligence. The differential diagnosis probability is represented by the bold blue bars in the circles, and the


probability of depression is represented by the gray bars.

Note: In case your patient has drug abuse, obtain the substance abuse pathologic page of QEEGhome by registering the diagnosis under the initial diagnoses section of the website.

#### References:

References:
Sadock, B. J., Sadock, V. A., & Ruiz, P. (Eds.). (2025). Kaplan and Sadock's comprehensive textbook of psychiatry (11th ed., Vols. 1–2). Wolters Kluwer
Sadock, B. J., Sadock, V. A., & Ruiz, P. (2022). Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry (12th ed.). Wolters Kluwer


#### User Manual







### **QEEG Based Predicting Medication Response**





#### **Explanation**

These two tables can be considered the most important finding that can be extracted from QEEG. To prepare this list, the NPCIndex Article Review Team has studied, categorized, and extracted algorithms from many authoritative published articles on predict medication response and Pharmaco EEG studies. These articles are published between 1970 and 2021. The findings extracted from this set include 85 different factors in the raw band domains, spectrum, power, coherence, and loreta that have not been segregated to avoid complexity, and their results are shown in these diagrams. One can review details in NPCIndex.com .

#### **Medication Recommendation**

These two charts, calculate response probability to various medications, according only to QEEG indicators. Blue charts favor drug response and red charts favor drug resistance. The longer the bar, the more evidence there is in the articles. Only drugs listed in the articles are listed. These tables present the indicators reviewed in the QEEG studies and are not a substitute for physician selection.





### **rTMS Response Prediction**

#### Network Performance


Accuracy: 92.10% Sensitivity: 89.13% Specificity: 97.47%

#### Participants Information







#### Features Information



#### Responsibility



#### Data Distribution




#### **About Predicting rTMS Response**


This index was obtained based on machine learning approaches and by examining the QEEG biomarkers of more than 470 cases treated with rTMS. The cases were diagnosed with depression (with and without comorbidity) and all were medication free. By examining more than 40 biomarkers capable of predicting response to rTMS treatment in previous studies and with data analysis, finally 10 biomarkers including bispectral and nonlinear features entered the machine learning process. The final chart can distinguish between RTMS responsive and resistant cases with 92.1% accuracy. This difference rate is much higher than the average response to treatment of 44%, in the selection of patients with clinical criteria, and is an important finding in the direction of personalized treatment for rTMS.





# Vigilance






### **EEG Neuromarker Values**

Neuromarker	Region	Value	Assessment
APF - E0	Frontal	11.00	High
APF - EC	Frontal	11.33	High
APF - EO	Occipital	10.88	High
APF - EC	Occipital	11.62	High
Alpha Asymmetry - EO	Frontal	00.05	Anxiety
Alpha Asymmetry - EC	Frontal	-0.11	Anhedonia
Alpha Asymmetry - EO	Occipital	00.05	Anxiety
Alpha Asymmetry - EC	Occipital	-0.07	Anhedonia
Beta Asymmetry - EO	Frontal	-0.09	Anxiety
Beta Asymmetry - EC	Frontal	-0.09	Anxiety
Alpha Blocking	O2	-	Observed
Arousal Level - EO		-	High
Arousal Level - EC		-	High
Vigilance Level - EO	<b>-</b>	04.00	Normal
Vigilance Level - EC	<del>-</del>	03.00	Normal
Vigilance Mean - EO	- <b>-</b>	04.05	Normal
Vigilance Mean - EC		02.41	Normal
Vigilance Regulation - EO	<b>-</b>	-0.27	Normal
Vigilance Regulation - EC		01.03	High
Vigilance 0 Stage (%) - EO	<u>-</u>	02.56	Normal
Vigilance 0 Stage (%) - EC		00.00	Normal
Vigilance A1 Stage (%) – E0	<b>-</b>	00.00	-
Vigilance A1 Stage (%) – EC	<b>-</b>	00.00	-





# **EEG Spectra**









### **Z Score Summary Information**


#### Eye Close



#### Eye Open




#### **Theta/Beta Ratio**








# **Absolute Power-Eye Close**




# **Relative Power-Eye Close**







# **Absolute Power-Eye Open**



# **Relative Power-Eye Open**

